Tricyclic dicarbonyl derivatives
AssigneeHoffmann-La Roche Inc.
InventorsBernd Buttelmann, Thierry Godel, Laurence Gross, Marie-Paule Heitz Neidhart, Claus Riemer, Rene Wyler
Life of this patent
Estimating the term…
Loading patent…
AssigneeHoffmann-La Roche Inc.
InventorsBernd Buttelmann, Thierry Godel, Laurence Gross, Marie-Paule Heitz Neidhart, Claus Riemer, Rene Wyler
Estimating the term…
Compounds of general formula (Ia), (Ib) and (II), wherein R.sup.1 and R.sup.2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R.sup.3 R.sup.4 NS(O).sub.2 -- and R.sup.3 and R.sup.4 signify lower alkyl, and R.sup.2 can additionally signify morpholino or thiomorpholino, a 5- or 6-membered heterocycle with 1-3N atoms optionally substituted by lower alkyl, hydroxy, amino or the group --CH.sub.2 NHCH.sub.3, a bicyclic heterocycle with 1-3N atoms or a group --NR.sup.5 R.sup.6 or --OR.sup.5 in which R.sup.5 and R.sup.6 can be the same or different and signify hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl or lower alkylamino-lower alkyl, and X in formula (II) signifies --CH.dbd.CH--, --CH.dbd.N--, --NH--, --CO-- or --O--, as well as pharmaceutically usable salts of compounds of general formula (Ia), (Ib) and (II). They can be used for the treatment or prevention of illnesses, especially for the treatment or prevention of ischemia, hypoglycaemia, hypoxia, cerebral vascular spasms, spasticity, trauma, hemorrhagia, infection (viral, bacterial, amoebic, prional), epileptic seizures, autoimmune diseases, withdrawal symptoms, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, intoxications, olivoponto-cerebellar atrophy, spinal cord injuries, schizophrenia, depressions, anxiety states, dependence, pains,autism and mental retardation.
A compound formula ##STR15## wherein R.sup.1 and R.sup.2 each independently is hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R.sup.3 R.sup.4 NS(O).sub.2 -- and R.sup.3 and R.sup.4 are lower alkyl, and
A compound of claim 2, 8-nitro-2,3,5,6-tetrahydro-1,2,4-triazolo4,3-c!-quinazoline-3,5-dione.
A compound of claim 2, 8,9-di-nitro-2,3,5,6-tetrahydro-1,2,4-triazolo4,3-c!-quinazoline-3,5-dion e.
A compound of claim 2, 9-bromo-8-nitro-2,3,5,6-tetrahydro-1,2,4-triazolo4,3-c-!-quinazoline-3,5- dione.
A compound of claim 2, 9-fluoro-8-nitro-2,3,5,6-tetrahydro-1,2,4-triazolo4,3-c!-quinazoline-3,5- dione.
A compound of claim 2, 9-chloro-8-nitro-2,3,5,6-tetrahydro-1,2,4-triazolo4,3-c!-quinazoline-3,5- dione.
A pharmaceutical composition comprising an effective amount of a compound of ##STR16## wherein R.sup.1 and R.sup.2 each independently is hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R.sup.3 R.sup.4 NS(O).sub.2 -- and R.sup.3 and R.sup.4 are lower alkyl, and
Dependencies are inferred from the claim text.